Market Overview

UPDATE: Oppenheimer Downgraded Zalicus

Related ZLCS
Morning Market Movers
Morning Market Movers

In a report published Monday, Oppenheimer analyst Boris Peaker downgraded Zalicus (NASDAQ: ZLCS) from Outperform to Perform and removed the $12.00 price target after disappointing Phase II studies of Z160.

Z160 was being evaluated in a Phase IIa for lumbosacral radiculopathy (LSR) and a second phase for postherpetic neuralgia (PHN) to demonstrate an improved bioavailability. The studies of Z160 did not demonstrate any difference from the placebo. Peaker reported, "Zalicus announced it will discontinue the development of Z160 and focus its efforts on Z944."

Zalicus closed at $4.69 on Friday and is currently trading down 72.28%.

Latest Ratings for ZLCS

Nov 2013WedbushDowngradesOutperformNeutral
Nov 2013OppenheimerDowngradesOutperformPerform
Oct 2012McNicoll Lewis VlakDowngradesHoldSell

View More Analyst Ratings for ZLCS
View the Latest Analyst Ratings

Posted-In: Boris Peaker OppenheimerAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (ZLCS)

View Comments and Join the Discussion!